Skip to main content
Sign In

Stephen C. Dreskin, MD, PhD - Professor

Division of Allergy and Clinical Immunology

Stephen Dreskin

Director, University of Colorado Allergy and Immunology Practice

Director, Allergy, Asthma, Immunology, Rhinology and Inflammation Pillar, University of Colorado Health Center for Lungs and Breathing


12700 E. 19th Avenue, B164, R2
Aurora, CO 80045

FOR APPOINTMENTS: Clinic Phone:     720-848-7600
Research Office Phone:     303-724-7190



5280 Top Doctors at UCH

New Procedure Helps Hospital Fight Antibiotic Allergies. UCH Insider.


1971 BA (Biochemistry) University of Pennsylvania

1976 PhD (Physiology) Emory University

1977 MD (Medicine) Emory University

1977-78 Internship (Internal Medicine) University of California-Davis

1978-80 Residency (Internal Medicine) University of California-Davis

1981-85 Fellowship - National Institute of Allergy & Infections Diseases (NIAID), NIH, Bethesda, MD


Board Certification:

1980 Internal Medicine

1983 Allergy and Immunology

1990 Diagnostic Laboratory Immunology

Severe allergic reactions, severe food allergies

Chronic Urticaria




Asthma and Rhinitis

Allergic Reactions to Vaccines

Allergy and Immunology Practice 

Clinic Location:

University of Colorado Allergy, Immunology and Rheumatology Practice

1635 Aurora Court
6th Floor, Anschutz Outpatient Pavilion
Aurora, CO 80045


Clinic Days:

Dr. Dreskin sees patients on Mondays and Thursdays.

These are teaching clinics. Dr. Dreskin does not have a "private" clinic. Often, patients will first be evaluated by an MD who is taking subspecialty training in Allergy and Immunology. Dr. Dreskin can be requested to be the "Attending of Record".


Appointment Contact:

Call 720-848-7600

Clinic Fax: 720-848-1713

For more information please see Dr. Dreskin's profile at

Molecular basis of peanut allergy

Study of functional IgE-allergen interactions as they pertain to food allergies

Molecular basis of chronic urticaria

The primary effort in the Dreskin laboratory is to understand the effector activity of peanut allergens (funded by the National Institutes of Allergy and Infectious Diseases,  RO1AI099029, Mapping the Critical Epitopes of Ara h 2 and Ara h 6).  Allergic reactions to peanuts occur because susceptible individuals have an aberrant response to peanuts by producing a plasma protein, IgE, that binds to the high affinity receptor for IgE on mast cells and basophils.  This receptor-bound IgE can be cross-linked by specific peanut proteins, called allergens, leading to a severe allergic reaction.  Eleven peanut proteins have been identified as allergens because they bind IgE from allergic individuals. Based on our work and the work of others, we now know that Ara h 2 and Ara h 6 are the most potent of these allergens for most patients.  We have championed the concept of defining the clinically most important allergens based on potency in functional assays that we have helped to develop.  Our newest data examining the allergenicity of peanut extracts that have been specifically depleted of Ara h 2  and Arah 6 demonstrate strongly that, for severely peanut allergic patients, the activity of Ara h 2 and Ara h6 together account for the approximately 90% of the allergenic activity of peanuts.  We propose to define in molecular detail how these peanut allergens interact to be responsible for mast cell activation in peanut allergic patients. We are currently testing our in vitro findings in vivo using a mouse model of peanut allergy. This approach has changed our thinking as to which peanut allergens are the most important for allergic reactions. 


Research Team:

Xueni Chen,  MD, PhD

Sumei Liao


Active Collaborators at UCDenver:

Kirk Hansen, PhD


1.    Otsu K and Dreskin SC. Peanut Allergy: An evolving clinical challenge.  Discovery Medicine 2012: 12(65): 319-328. PMID: 22031669
2.    Kulis M, Chen X, Lew J, Wang Q, Ojas Patel P, Zhuang Y, Murray KS, Duncan MW, Porterfield HS, Burks AW, Dreskin SC.  The 2S albumin allergens of Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of anaphylaxis and can effectively desensitize peanut-allergic mice. Clin Exp Allergy. 2012 Feb;42(2):326-36. PMID:22288514
3.    Zhuang Y and Dreskin SC.  Redefining the major peanut allergens. Immunol Res. 2013 Mar;55(1-3):125-34. PMID: 22948807.
4.    Zhuang Y, Durrani S, Hodges BD, Dreskin SC, Chen X. Expression of recombinant Ara h 6 in Pichia pastoris but not in E. coli preserves allergic effector function and allows assessment of specific mutations Mol Nutr Food Res. 2012 Jun;56(6):986-95. PMID:22707273.
5.    Chen X, Wang Q, El-Mezayen R, Zhuang, Y, and Dreskin SC. The allergic effector activity of a crude peanut extract: Ara h 2 and Ara h 6 are equipotent and substantially redundant. Int Arch Allergy Immunol. 2013;160(3):251-8. PMID: 23075924
6.    Go AC, Barber GR, Dreskin SC.  Implementing standardized intravenous antibiotic desensitizations among hospital inpatients. Am J Health Syst Pharm. 2013 Mar 15;70(6):540-8. doi: 10.2146/ajhp110718.  PMID: 23456408.
7.   Pahud BA, Williams SE, Dekker CL, Halsey N, Larussa P, Baxter RP, Klein NP, Marchant CD, Sparks RC, Jakob K, Aukes L, Swope S, Barnett E, Lewis P, Berger M, Dreskin SC, Donofrio PD, Sejvar JJ, Slade BA, Gidudu J, Vellozzi C, Edwards KM.  Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination. J. 2013 Feb;32(2):163-8. PMID: 23334340.
8.    Halsey NA, Griffioen M, Dreskin SC, Dekker C, Wood R, Sharma D, Jones JF. LaRussa PF, Garner J, Berger M, Velozzi C, and the Hypersensitivity Working Group of the Clinical Immunization Safety Assessment network Immediate Hypersensitivity Reactions Following Monovalent 2009 Pandemic Influenza A (H1N1) Vaccines: Reports to VAERS.  Vaccine 31 (2013) 6107– 6112. UI: 24120547.
9.  Koid AE, Chapman MD, Hamilton RG, Van Ree R, Versteeg SA, Dreskin SC, Koppelman SJ, Wuenschmann S  Ara h 6 complements Ara h 2 as an Important Marker for IgE Reactivity to Peanut.  J Agric Food Chem. 2014; 62: 206-213.  PMID: 24328145
10.  Mills K. Lay J. Wu W. Robinette C. Kesic MJ. Dreskin SC. Peden DB. Hernandez M.  Vitamin E, -tocopherol, diminishes ex vivo basophil response to dust mite allergen.  Allergy. 69(4):541-4, 2014. UI 24697338.
11.  Bernard H, Guillon B, Drumare M-F, Paty E, Dreskin SC, Wal J-M, Adel-Patent K, and Hazebruck S.  Allergenicity of peanut component Ara h 2: contribution of conformational versus linear hydroxyproline-containing epitopes. J Allergy Clin Immunol. 2014; 6749(14); 1520-6. PMID: 25483599.
12.  Otsu K, Guo R, Dreskin SC.  Epitope analysis of Ara h 2 and Ara h 6:  characteristic patterns of IgE-binding fingerprints among individuals with similar clinical histories. Clin Exp Allergy. 2015; 45(2):471-84.  PMID: 25213872
13.  Patel OP, Giorno RC, Dibbern DA, Andrews KY, Durairaj S, and Dreskin SC.  A Preliminary Study of Gene Expression Profiles in Chronic Idiopathic (spontaneous) Urticaria.  Allergy & Rhinology. 2015 Jan;6(2):101-10.  PMID: 26302730.
14.  Moutsouglou, D and Dreskin SC.  B cells establish, but do not maintain, long-lived murine anti-peanut IgE.  In Press, Clinical and Experimental Allergy, 2016.
15.  International Consensus (ICON): Allergic Reactions to Vaccines. Stephen C. Dreskin, Neal A. Halsey, John M. Kelso, Robert A. Wood, Donna S Hummell, Kathryn M. Edwards, Jean-Christoph Caubet, Renata J. M. Engler, Michael S Gold, Claude Ponvert , Pascal Demoly, Mario Sanchez Borges, Antonella Muraro, James T. Li, Menachem Rottem, and Lanny J. Rosenwasser. In Press, Journal of the World Allergy Organization, 2016.